Peptides have had a genuine “craze” over the past couple of years. Search interest has climbed steadily, driven partly by the wider conversation around weight-loss and metabolic treatments, and partly by a growing community of people online sharing personal experiences with recovery, gut health, and general wellbeing.
Whatever the reason someone first encounters the term, the enthusiasm is there, and for many people, it’s the first time they’ve properly considered what a peptide actually is.
Put simply, peptides are short chains of amino acids, the same building blocks that make up proteins, just smaller and more targeted in what they do.
That size is exactly why the administration method is also an important factor to consider. Due to peptides being structurally delicate, how they’re administered can significantly affect whether they survive long enough to have any effect at all.
Much of the public’s familiarity with peptides has come through injectable weight-loss treatments, a format people adapted to remarkably quickly given how recently these drugs entered mainstream use.
What’s less widely known is that peptides come in capsule form too, and for some compounds, that is not a new or experimental idea at all.
As research into individual compounds has matured, peptide capsules have proven a reliable route for certain peptides in their own right, rather than simply a more convenient substitute for injecting
Injection has traditionally been the more reliable route, since it bypasses digestion entirely and delivers the compound directly into the body.
Capsules face a slightly tougher journey: stomach acid and digestive enzymes are specifically designed to break down protein-like structures, which historically made oral peptides difficult to formulate effectively.
BPC-157 is a useful example of why this varies so much by compound. Unlike most peptides, it’s shown unusual stability in acidic conditions in lab studies, remaining intact for over 24 hours where others would break down almost immediately.
That resilience is part of why it’s been studied both as an injectable and as an oral compound, an option that simply isn’t available for every peptide.
KPV, a smaller anti-inflammatory peptide often discussed in the same gut-health research context, has been studied in both formats too.
Larazotide acetate works differently again. Rather than being an alternative delivery method for a compound that could otherwise be injected, it’s designed specifically to act locally within the gut lining without entering the bloodstream at all.
It’s currently studied as an investigational compound under active clinical trial status, and an injectable version wouldn’t make sense given how it’s meant to work.
What these examples point to is a broader principle, understanding that the format a peptide comes in usually reflects years of specific research into how that particular compound behaves in the body, greater than a matter of convenience or preference.
Capsules are not a shortcut version of injections, and injections do not automatically mean a “stronger” option; each format exists because of how a specific peptide is absorbed, where it needs to act, and what the research supporting it has actually shown.
It’s also worth being clear about where all of this currently sits regulatorily. None of the compounds discussed here are approved medicines in the UK. They’re sold and studied under a research-use classification, intended for research purposes only rather than human treatment.
David Prior
David Prior is the editor of Today News, responsible for the overall editorial strategy. He is an NCTJ-qualified journalist with over 20 years’ experience, and is also editor of the award-winning hyperlocal news title Altrincham Today. His LinkedIn profile is here.
